UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Poor planning undermines budget success; explore effective forecasting, set realistic goals, and implement steady review to keep your finances on course.
21,420 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
A major fund’s exit from Ocular Therapeutix raises questions about timing, liquidity, and sector signals. This articl...
Metropolis has surged to a $5 billion valuation after a 2025 funding round, transforming parking networks into a broa...
As Palantir hype cools, two AI-driven cash-flow engines emerge as steadier bets. This report explains why Alphabet an...
After years of headwinds, Target is showing early signs of life. Yet the stock price tells a story of cautious optimi...
The SonicShares Global Shipping ETF BOAT surged 51% over the past year, yet its quarterly payouts remain highly volat...
A high-profile venture capital tie-up is stirring markets as a rising firm expands rapidly. Reports say Donald Trump ...
As Berkshire Hathaway's leadership evolves, investors wonder if berkshire hathaway greg abel has echoed Warren Buffet...
Three leading space names moved higher in a risk-on trading session, with AST SpaceMobile, Rocket Lab and Planet Labs...
With oil prices near a year high, IEO’s $0.55 quarterly dividend is set to be tested by producer payouts and market s...
A major fund plowed into a top U.S. homebuilder with a $65 million stake, ahead of a rumored $47-per-share buyout. He...
Elon Musk’s clash with OpenAI doubles as a bid to launch xAI, with Tesla financing and strategic partnerships setting...